New York State Medicaid
Preferred Drug Program - 2021 Therapeutic Class Review

The New York Medicaid Drug Utilization Review (DUR) Board intends to review the following therapeutic classes in 2021 as they pertain to the fee-for-service (FFS) Preferred Drug Program (PDP). For the therapeutic classes (provided below), new relevant clinical and/or financial information is known to exist. DUR Board meeting agendas for 2021 are posted to the Department of Health (DOH) website thirty days prior to the meeting date.

Therapeutic Category	Therapeutic Class	Previous Review Date
Analgesics	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	07/23/2020
Anti-Infectives	Antibiotics - Inhaled	09/17/2015
Cardiovascular	Triglyceride Lowering Agents	04/22/2015
Central Nervous System	Anticonvulsants - Other	05/16/2019
	Antimigraine Agents, Other	05/16/2019
Hematological Agents	Colony Stimulating Factors	05/16/2019
Ophthalmics	Anti-inflammatories/Immunomodulators - Ophthalmic	09/20/2018
Otics	Fluoroquinolones - Otic	04/27/2017
Renal and Genitourinary	Antihyperuricemics	05/16/2019
Respiratory	Anticholinergics/COPD Agents	05/16/2019

The current preferred and non-preferred status of drugs subject to the PDP may be viewed at https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf

At this time, no relevant new clinical and/or financial information is known to exist for the remaining PDP therapeutic classes since previously reviewed and the DOH proposes no changes to the Preferred Drug List (PDL). If interested parties have new relevant clinical information, please submit to the Medicaid Pharmacy Department (dur@health.ny.gov) in a

timely manner. The DOH will consider any new relevant clinical information provided when developing future DUR Board meeting agendas.

In determining new clinical information, the previous review dates for all therapeutic classes are available on prior meeting agendas which may be viewed at http://www.health.ny.gov/health_care/medicaid/program/dur

New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials. Comparative evidence is preferred, or placebo controlled when no head-to-head trials are available. Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of review and submission is discouraged.

Those wishing to submit new clinical information may do so as it becomes available. New information is preferred in an electronic format and may be submitted to dur@health.ny.gov (please reference DUR Board PDP Review).

Please continue to monitor the DOH web-site for DUR Board meeting schedules and agendas at http://www.health.ny.gov/health_care/medicaid/program/dur